Company intelligence / Profile preview
Huashen Pharmaceutical
Jiangsu, Chinahuashenbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The now-dissolved Shijiazhuang/NCPC joint venture developed and commercialized butylphthalide for stroke treatment in China. Other current "Huashen" companies focus on pharmaceutical manufacturing or cosmetic biotech products.
- Therapeutic areas
- DermatologyNeurology
- Modalities
- Small molecule drugBiologic/cosmetic ingredients
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
North China Pharmaceutical GroupLong Win FinanceWincentus
Beyond the preview
Go deeper on Huashen Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huashen Pharmaceutical.